HCM: HUTCHMED Ltd Company Short-Term Debts

Symbol and logo of brand HUTCHMED (HCM)

HUTCHMED (China) Limited's expansion strategy in the US and China drives the dynamics of short-term loan capital, where the indicator level stands at 0.01. This biopharmaceutical company relies on the B2B segment of oncology centers and targeted therapy. Business growth is based on the launch of new drugs, making the company independent of macro cycles. An analysis of the debt curve allows for an assessment of the business's real credit load.

HCM Hutchison MediPharma Company Short-Term Debt (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company HUTCHMED Corp (HCM)

- current quotes and average value forecast:
Price Chart HUTCHMED|HCM - Fair Value Consensus
- market capitalization information:
Market Capitalization HUTCHMED (China) Limited|HCM - Enterprise Value
- business book valuation details:
Net Assets per Single Share HUTCHMED|HCM - Company Book Value|Market Cap to Net Assets Ratio hutch-med.com|HCM - Aggregate Asset Value
- debt level and financial liquidity data:
Debt to Equity HUTCHMED (China) Limited|HCM - Long-Term Liabilities to Capital|Short-Term Debt to Equity HUTCHMED (China) Limited|HCM - Company Aggregate Debt|Debts to Book Capitalization HUTCHMED (China) Limited|HCM - Company Long-Term Liabilities|Company Short-Term Debt HUTCHMED|Quick Liquidity hutch-med.com
- earnings and multiples data:
HCM - Company Net Income
Fundamental valuation:HUTCHMED (HCM)
Mass-produced product of HUTCHMED (China) Limited

The market evaluates the potential of HUTCHMED (China) Limited (HCM) through the lens of clinical success, where short-term debts measure liquidity and the company's ability to service obligations within a year. Analyzing the current debt obligations chart, an investor sees the financial stability of a biotech business whose capital requirements for fighting oncology remain independent of macroeconomic cycles or GDP fluctuations.

Competitor analysis

INCY - Company Short-Term Debt|Company Short-Term Loans and Borrowings NUVB (Nuvation Bio Inc)|DAWN: Company Short-Term Debts|Monopar Corp (MNPR) - Company Short-Term Debts|Company Short-Term Debt Inhibrx Biosciences|Company Short-Term Debt IMAB|Company Current Liabilities FENC (Fennec Pharmaceuticals Inc.)|HRTX (herontx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Nuvectis NVCT|Coherus BioSciences (CHRS) - Short-Term Debt|CRBP - Company Short-Term Debt|CRDF (Cardiff Oncology, Inc.) - Company Short-Term Indebtedness|BYSI: Company Short-Term Debts|Company Current Liabilities BioAtla|Company Short-Term Debt Lixte Biotechnology Holdings|Short-Term Debt Citius Pharma CTXR|Company Short-Term Debt Cellectar Biosciences (CLRB)|Company Short-Term Debt BLRX (biolinerx.com)|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. (APRE) - Short-Term Debt|Kazia - Company Short-Term Debts|Short-Term Indebtedness Silexion Therapeutics Corp (SLXN)|NCNA (nucana.com) - Company Current Liabilities|Short-Term Debt chimerix.com (CMRX)|Company Current Liabilities CYCC|GTHX: Company Short-Term Loans and Borrowings|Company Current Liabilities KRON (Kronos Bio Corp)|Amount of Current Liabilities KTRA|Company Short-Term Debts ONCT (Oncternal Therapeutics)|Company Short-Term Loans and Borrowings PRTG